CTLT Quote, Financials, Valuation and Earnings

Eli Lilly and has a net margin of -12.61% compared to Catalent's net margin of 8.48%. Catalent's return on equity of -11.29% beat Eli Lilly and's return on equity of 66.4%.

Catalent has a consensus price target of $63.50, signalling downside risk potential of -0.08%. On the other hand Eli Lilly and has an analysts' consensus of $984.05 which suggests that it could grow by 28.17%. Given that Eli Lilly and has higher upside potential than Catalent, analysts believe Eli Lilly and is more attractive than Catalent.

Catalent has a beta of 1.146, which suggesting that the stock is 14.582% more volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.409, suggesting its less volatile than the S&P 500 by 59.07%.

Catalent has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly and offers a yield of 0.68% to investors and pays a quarterly dividend of $1.30 per share. Catalent pays -- of its earnings as a dividend. Eli Lilly and pays out 77.65% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Catalent quarterly revenues are $1B, which are smaller than Eli Lilly and quarterly revenues of $11.4B. Catalent's net income of -$129M is lower than Eli Lilly and's net income of $970.3M. Notably, Catalent's price-to-earnings ratio is -- while Eli Lilly and's PE ratio is 83.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Catalent is 2.61x versus 16.99x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

MAIA Biotechnology has a net margin of -12.61% compared to Catalent's net margin of --. Catalent's return on equity of -11.29% beat MAIA Biotechnology's return on equity of --.

Catalent has a consensus price target of $63.50, signalling downside risk potential of -0.08%. On the other hand MAIA Biotechnology has an analysts' consensus of $12.63 which suggests that it could grow by 525%. Given that MAIA Biotechnology has higher upside potential than Catalent, analysts believe MAIA Biotechnology is more attractive than Catalent.

Catalent has a beta of 1.146, which suggesting that the stock is 14.582% more volatile than S&P 500. In comparison MAIA Biotechnology has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Catalent has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. MAIA Biotechnology offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Catalent pays -- of its earnings as a dividend. MAIA Biotechnology pays out -- of its earnings as a dividend.

Catalent quarterly revenues are $1B, which are larger than MAIA Biotechnology quarterly revenues of --. Catalent's net income of -$129M is lower than MAIA Biotechnology's net income of -$2.7M. Notably, Catalent's price-to-earnings ratio is -- while MAIA Biotechnology's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Catalent is 2.61x versus -- for MAIA Biotechnology. Usually stocks with elevated PS ratios are considered overvalued.

Merck & has a net margin of -12.61% compared to Catalent's net margin of 18.95%. Catalent's return on equity of -11.29% beat Merck &'s return on equity of 29.26%.

Catalent has a consensus price target of $63.50, signalling downside risk potential of -0.08%. On the other hand Merck & has an analysts' consensus of $128.73 which suggests that it could grow by 31.29%. Given that Merck & has higher upside potential than Catalent, analysts believe Merck & is more attractive than Catalent.

Catalent has a beta of 1.146, which suggesting that the stock is 14.582% more volatile than S&P 500. In comparison Merck & has a beta of 0.393, suggesting its less volatile than the S&P 500 by 60.746%.

Catalent has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & offers a yield of 3.18% to investors and pays a quarterly dividend of $0.81 per share. Catalent pays -- of its earnings as a dividend. Merck & pays out 2039.73% of its earnings as a dividend.

Catalent quarterly revenues are $1B, which are smaller than Merck & quarterly revenues of $16.7B. Catalent's net income of -$129M is lower than Merck &'s net income of $3.2B. Notably, Catalent's price-to-earnings ratio is -- while Merck &'s PE ratio is 20.56x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Catalent is 2.61x versus 3.95x for Merck &. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer has a net margin of -12.61% compared to Catalent's net margin of 25.23%. Catalent's return on equity of -11.29% beat Pfizer's return on equity of 4.63%.

Catalent has a consensus price target of $63.50, signalling downside risk potential of -0.08%. On the other hand Pfizer has an analysts' consensus of $31.86 which suggests that it could grow by 20.88%. Given that Pfizer has higher upside potential than Catalent, analysts believe Pfizer is more attractive than Catalent.

Catalent has a beta of 1.146, which suggesting that the stock is 14.582% more volatile than S&P 500. In comparison Pfizer has a beta of 0.653, suggesting its less volatile than the S&P 500 by 34.739%.

Catalent has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer offers a yield of 6.37% to investors and pays a quarterly dividend of $0.42 per share. Catalent pays -- of its earnings as a dividend. Pfizer pays out 436.39% of its earnings as a dividend.

Catalent quarterly revenues are $1B, which are smaller than Pfizer quarterly revenues of $17.7B. Catalent's net income of -$129M is lower than Pfizer's net income of $4.5B. Notably, Catalent's price-to-earnings ratio is -- while Pfizer's PE ratio is 35.62x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Catalent is 2.61x versus 2.52x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.